Investigational drugs for the treatment of binge eating disorder (BED): an update
| Autor: | Susan L. McElroy, José Carlos Appolinario, Antonio Egidio Nardi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Functional impairment Dopamine Dopamine neurotransmission 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Drug Development Reward Binge-eating disorder medicine Animals Humans Pharmacology (medical) Intensive care medicine Pharmacology business.industry Drugs Investigational General Medicine medicine.disease Eating disorders 030104 developmental biology Lisdexamfetamine 030220 oncology & carcinogenesis Investigational Drugs business Dasotraline Binge-Eating Disorder medicine.drug |
| Zdroj: | Expert Opinion on Investigational Drugs. 28:1081-1094 |
| ISSN: | 1744-7658 1354-3784 |
| DOI: | 10.1080/13543784.2019.1692813 |
| Popis: | Introduction: Binge eating disorder (BED) is the most common eating disorder and is frequently associated with psychiatric and medical comorbidities and functional impairment. Although psychological treatments have been the cornerstones of BED treatment, pharmacologic interventions also play an important part of the multimodal management of this condition.Areas covered: This review examines investigational, approved and other pharmacological agents for the treatment of BED. We searched PubMed and clinicaltrials.gov to identify pharmacological interventions for the management of this condition.Expert opinion: BED pharmacological studies have incorporated new drug targets based on our enhanced understanding of the pathophysiology of BED. Neurobiological dysregulation in the reward center and impulse control circuitry and related disturbances in dopamine neurotransmission are among the neurobiological explanations that have been suggested for BED. These mechanisms serve as a pharmacodynamic foundation for the development of new compounds such as lisdexamfetamine (LDX) and dasotraline. Despite these advances, pharmacological trials in BED have numerous challenges that must be overcome. For most compounds studied, larger and more definitive trials is a high priority. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|